Filippo Caraci is an expert in Pharmacy at University of Catania (Italy). As of October 2026, ScienceLeadR ranks Filippo Caraci in the top 1% of experts worldwide for Neurocognitive Disorders. Filippo Caraci has authored 331 publications, the most recent in 2026, and is an investigator in 1 clinical trial. SLR score: 948 (community average: 125). How the SLR is computed.

LeadR Profile

Filippo Caraci University of Catania Italy
948 ScienceLeadR Reputation 948
Network Map

Pharmacy

Subspecialties: Psychiatry - Neurology - Nutrition

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2003 - 2026

Source: PubMed

University of Catania

Publications Synthesis

Sources: PubMed, OpenAlex

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Exploring sexuality, sexual well-being and intimacy in schizophrenia spectrum disorders: systematic review and meta-synthesis of qualitative studies.
PMID 42869998 — schizophrenia, sexuality, antipsychotic agents, nervous system diseases, wounds and injuries, psychiatry
Eur Arch Psychiatry Clin Neurosci20260
Dietary (Poly)phenol Intake, Inflammatory Biomarkers, and Mild Cognitive Impairment in Italian Adults.
PMID 42792219 — flavanones, phenols, brain, cognitive dysfunction, biomarkers, diet, cognition disorders, lignans, flavones, flavonoids, phenol, cognition, anthocyanins
Antioxidants (Basel)20260
Reconceptualizing Schizophrenia through a Patient-Oriented Perspective: a Systematic Review and Qualitative Meta-Synthesis.
PMID 42786718 — fear, cognitive dysfunction, signs and symptoms, schizophrenia, cognition disorders
Schizophr Bull20260
The role of metacognitive beliefs in impulse control disorders and addictive-like behaviors in Parkinson's disease: an exploratory study.
PMID 42756337 — parkinson disease, metacognition, disruptive, impulse control, and conduct disorders, dopamine, therapeutics
Front Psychiatry20260
Alterations of gut microbiota in Down syndrome and their association with Alzheimer's disease.
PMID 42712102 — dementia, down syndrome, alzheimer disease, biomarkers, metagenomics, gastrointestinal microbiome, microbiota, plasma
Alzheimers Dement20260

Clinical Studies 1

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 1

By status:

Completed 1

By type:

Interventional 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

Cohort/Consortium Investigators 6

LeadR Networks

Main global connection map